CORXEL Announces Acceptance of NDA for Aficamten
LEI: 549300Q7EXQQH6KF7Z84
15 November 2024
RTW Biotech Opportunities Ltd
CORXEL Announces Acceptance of NDA for Aficamten
RTW Biotech Opportunities Ltd (the "Company"), a London Stock Exchange-listed investment company focused on identifying transformative assets with high growth potential across the life sciences sector, is pleased to note the announcement by portfolio company, CORXEL Pharmaceuticals ("CORXEL"), of the acceptance by China's National Medical Products Administration (NMPA) of the New Drug Application (NDA) for Aficamten for the treatment of obstructive hypertrophic cardiomyopathy (HCM).
Aficamten is an investigational, next-in-class selective small molecule cardiac myosin inhibitor. It received Breakthrough Therapy Designation for the treatment of symptomatic obstructive HCM from the U.S. Food & Drug Administration (FDA) as well as the NMPA. HCM is a genetic heart disease in which the heart muscle becomes abnormally thick and ultimately limits the heart's pumping function. It is the most common inherited cardiovascular disorder, with approximately 132,000-330,000 patients diagnosed in China and an estimated 748,000-1,870,000 who remain undiagnosed.
CORXEL, formerly called Ji Xing Pharmaceuticals, is a leading biotech company committed to bringing innovative science and medicines to underserved patients with cardiometabolic diseases. CORXEL was founded and launched by RTW Investments (the "Investment Manager") in 2019. In July 2020, CORXEL entered into a license and collaboration agreement with Cytokinetics, a late-stage biopharmaceutical company headquartered in California, pursuant to which Cytokinetics granted CORXEL an exclusive license to develop and commercialise Aficamten in Greater China.
Roderick Wong, Managing Partner and CIO at the Investment Manager commented on the news, "We are thrilled to see the acceptance of the NDA for Aficamten, a significant milestone for CORXEL and a testament to its commitment to bringing innovative therapies to patients with cardiometabolic diseases. This achievement underscores the dedication and hard work of the CORXEL team. We look forward to continuing to support them in their efforts to deliver groundbreaking treatments that address unmet medical needs and improve patient outcomes."
The full text of the announcement can be accessed here.
For Further Information
|
RTW Investments, LP |
+44 20 7959 6361 |
|
Woody Stileman, Managing Director, Business Development
Krisha McCune, Director, Investor Relations |
|
|
Cadarn Capital (PR & Communications / Distribution & IR Partner)
Lucy Clark (PR)
David Harris (Distribution) |
+44 79 8418 4461 +44 73 6888 3211 david@cadarncapital.com |
|
Deutsche Numis (Joint Corporate Broker)
Freddie Barnfield |
+44 20 7260 1000 |
|
Nathan Brown |
|
|
Euan Brown |
|
|
BofA Securities (Joint Corporate Broker) |
+44 20 7628 1000 |
|
Edward Peel |
|
|
Alex Penney |
|
|
Elysium Fund Management Limited
Joanna Duquemin Nicolle, Chief Executive Officer
Sadie Morrison, Managing Director
|
+44 14 8170 3100 |
|
Morgan Stanley Fund Services USA LLC |
+1 914 225 8885 |
|
|
|
About Biotech Opportunities Ltd:
RTW Biotech Opportunities Ltd (LSE: RTW) is an investment fund focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors. Driven by a long-term approach to support innovative businesses, RTW Biotech Opportunities Ltd invests in companies developing next-generation therapies and technologies that can significantly improve patients' lives. RTW Biotech Opportunities Ltd is managed by RTW Investments, LP, a leading healthcare-focused entrepreneurial investment firm with deep scientific expertise and a strong track record of supporting companies developing life-changing therapies.
Visit the website at www.rtwfunds.com/rtw-biotech-opportunities-ltd for more information.
***********
The information in this announcement may include forward-looking statements, which are based on the current expectations and projections about future events, and in certain cases can be identified by the use of terms such as "may", "will", "should", "expect", "anticipate", "project", "estimate", "intend", "continue", "target", "believe" (or the negatives thereon) or other variations thereon or comparable terminology. These forward-looking statements, as well as those included in any related materials, are subject to risks, uncertainties and assumptions about the Company and/or its underlying investments, including, among other things, the development of the applicable entity's business, trends in its operating industry, expected use of financing proceeds and future capital expenditures and acquisitions. In light of these risks, uncertainties and assumptions, the events in the forward-looking statements may not occur.
The information contained in this announcement is given at the date of its publication (unless otherwise marked). No reliance may be placed for any purpose whatsoever on the information or opinions contained in this announcement or on its completeness, accuracy or fairness.
***********
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 1 day ago Savannah Energy
- 2 days ago Buccaneer Energy PLC
- 2 days ago Savannah Energy
- 2 days ago Carclo
- 2 days ago Schroder Japan Growth Fund